MIR 19 ®

DRUG2 trials

Sponsors

National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia

Conditions

COVID-19

Phase 2

Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19

CompletedNCT05184127

National Research Center - Institute of Immunology Federal Medical-Biological Agency of RussiaCOVID-19

Start: 2021-04-27End: 2021-09-07Updated: 2022-01-11

Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19

CompletedNCT05783206

National Research Center - Institute of Immunology Federal Medical-Biological Agency of RussiaCOVID-19

Start: 2022-02-10End: 2023-07-28Updated: 2023-12-27

Related Papers

Phase 2‐3 Trial: Prevention of the Progression to Moderate and Severe <scp>COVID</scp>‐19 in <scp>SARS</scp>‐<scp>CoV</scp>‐2‐Infected Non‐Hospitalized Adults With Inhaled <scp>siRNA</scp>‐Based <scp>MIR</scp> 19

Allergy2025-03-031 citations

Treatment of <scp>COVID</scp>‐19 patients with a <scp>SARS‐CoV</scp>‐2‐specific <scp>siRNA</scp>‐peptide dendrimer formulation

Allergy2023-02-0127 citations